Virax Biolabs Group Business Summary

Virax Biolabs Group Ltd (VRAX) is a commercial-stage biotechnology company specializing in immunology profiling and the detection of T-cell responses to viral diseases. The company generates revenue through a dual-track model: the sale of proprietary diagnostic products, including ELISpot kits and ImmuneSelect peptide pools, and the provision of specialized immunology services. Its primary business segments are divided between the ViraxImmune™ platform, which focuses on clinical-grade diagnostics for post-acute infection syndromes (PAIS) such as Long COVID and ME/CFS, and the ImmuneSelect Research Use Only (RUO) portfolio, designed to provide recurring revenue from the global research community. As of early 2026, the company is transitioning from clinical recruitment to data readout, with major UK trial results expected in Q2 2026. Direct competitors include Qiagen N.V., Fulgent Genetics, and Oxford Immunotec (PerkinElmer), against whom Virax differentiates itself by focusing specifically on T-cell dysfunction as a primary biomarker for chronic post-viral conditions. Leadership is spearheaded by co-founder James Foster, who serves as Chairman, CEO, and acting CFO following a 2025 executive transition; Foster brings extensive pedigree in MedTech commercialization and product development. He is supported by Chief Operating Officer Dr. Nigel McCracken, a veteran biopharmaceutical executive with prior leadership roles at BerGenBio and NuCana PLC, and co-founder Cameron Shaw, who oversees strategic innovation. The company’s governance is bolstered by a board of directors that includes finance executive Nelson Haight and independent director Dr. Iain Miller, an expert in healthcare strategy. Notable institutional involvement includes H.C. Wainwright & Co., which recently acted as the exclusive placement agent for a $5 million private placement intended to extend the company's cash runway through the completion of its FDA and MHRA regulatory submissions in 2028.